| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699867 | Clinical Oncology | 2006 | 5 Pages |
Abstract
Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Michels, T. Geldart, A. Darby, L. Craddock, A. Iveson, L. Richardson, T. Iveson,